Priyanka Koshy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Priyanka Koshy has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Maarten Naesens
Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium
16 shared publications - Thibaut Vaulet
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
12 shared publications - Dirk Kuypers
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
9 shared publications - Elisabet Van Loon
Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium; Department of Nephrology and Kidney Transplantation, University Hospital Leuven, Leuven, Belgium
8 shared publications - Maarten Coemans
Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
8 shared publications - Jasper Callemeyn
Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium; Department of Nephrology and Kidney Transplantation, University Hospital Leuven, Leuven, Belgium
7 shared publications
Latest Publications
- Open Access
Continuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.
Open AccessContinuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.
- 14 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2262-2274
Clinical Relevance of Donor-Derived cfDNA In Monitoring Kidney Transplant Rejection
Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.
- 14 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2262-2274
Clinical Relevance of Donor-Derived cfDNA In Monitoring Kidney Transplant Rejection
Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.
- Open Access
- 27 April 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (5) , 1-14
Belgian recommendations for tissue diagnosis of amyloidosis
Amyloidosis is a disorder caused by the extracellular deposition of misfolded protein fibrils, leading to organ dysfunction. Diagnosis remains challenging due to non-specific clinical presentations and the diversity of amyloid subtypes. Accurate identification of the amyloid precursor protein is key for prognostication and treatment strategy. This document aims to provide practical recommendations for the tissue diagnosis of amyloidosis within the Belgian healthcare context. It targets clinicians managing amyloidosis patients and pathologists evaluating biopsies with suspected amyloid deposits. A structured PubMed search ('amyloidosis AND biopsy AND stain*'; 'amyloidosis AND mass spectro*') was conducted in August 2025. After exclusion of case reports, preclinical studies, and Alzheimer-related articles, 298 publications were reviewed. Recommendations were formulated based on available evidence and discussed among Belgian clinical and pathology experts. Key recommendations emphasize that tissue biopsies remain essential for amyloidosis diagnosis and typing. Congo red staining with birefringence and fluorescence confirmation is required. Immunohistochemistry and immunofluorescence are first-line subtyping tools, while mass spectrometry serves as a reference method when results remain inconclusive. Centralization of complex analyses in experienced centres is encouraged. These recommendations promote standardized, early and accurate tissue diagnosis of amyloidosis in Belgium, supporting optimal patient management and harmonization of diagnostic practices across institutions.
- 27 April 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (5) , 1-14
Open AccessBelgian recommendations for tissue diagnosis of amyloidosis
Amyloidosis is a disorder caused by the extracellular deposition of misfolded protein fibrils, leading to organ dysfunction. Diagnosis remains challenging due to non-specific clinical presentations and the diversity of amyloid subtypes. Accurate identification of the amyloid precursor protein is key for prognostication and treatment strategy. This document aims to provide practical recommendations for the tissue diagnosis of amyloidosis within the Belgian healthcare context. It targets clinicians managing amyloidosis patients and pathologists evaluating biopsies with suspected amyloid deposits. A structured PubMed search ('amyloidosis AND biopsy AND stain*'; 'amyloidosis AND mass spectro*') was conducted in August 2025. After exclusion of case reports, preclinical studies, and Alzheimer-related articles, 298 publications were reviewed. Recommendations were formulated based on available evidence and discussed among Belgian clinical and pathology experts. Key recommendations emphasize that tissue biopsies remain essential for amyloidosis diagnosis and typing. Congo red staining with birefringence and fluorescence confirmation is required. Immunohistochemistry and immunofluorescence are first-line subtyping tools, while mass spectrometry serves as a reference method when results remain inconclusive. Centralization of complex analyses in experienced centres is encouraged. These recommendations promote standardized, early and accurate tissue diagnosis of amyloidosis in Belgium, supporting optimal patient management and harmonization of diagnostic practices across institutions.
- Open Access
- 25 March 2026
- Published by Springer Nature in Research Square
Cytomegalovirus Infection Determines Microvascular Inflammation Risk beyond Alloimmunity in Kidney Transplantation
Microvascular inflammation (MVI) is a major determinant of kidney allograft failure, yet its upstream drivers remain incompletely defined. Natural killer (NK) cells contribute to donor-specific antibody (DSA)-positive and DSA-negative MVI via antibody-dependent cytotoxicity and missing-self recognition. Cytomegalovirus (CMV) infection durably remodels the NK cell compartment, inducing memory-like populations with heightened effector function. In a contemporary multicenter cohort of 4,411 kidney transplants with 10,214 post-transplant biopsies in the CMV prophylaxis era, CMV seropositivity, indicative of prior infection, was independently associated with a twofold higher hazard of MVI and increased graft failure. This association extended across antibody-mediated and DSA-negative, C4d-negative MVI and acted synergistically with HLA-DSA and missing self. Post-transplant CMV replication and disease were associated with subsequent MVI only in seronegative recipients, consistent with an effect of primary CMV infection. Together, these findings identify CMV infection as a clinically relevant and previously underrecognized determinant of MVI, beyond alloimmune factors.
- 25 March 2026
- Published by Springer Nature in Research Square
Open AccessCytomegalovirus Infection Determines Microvascular Inflammation Risk beyond Alloimmunity in Kidney Transplantation
Microvascular inflammation (MVI) is a major determinant of kidney allograft failure, yet its upstream drivers remain incompletely defined. Natural killer (NK) cells contribute to donor-specific antibody (DSA)-positive and DSA-negative MVI via antibody-dependent cytotoxicity and missing-self recognition. Cytomegalovirus (CMV) infection durably remodels the NK cell compartment, inducing memory-like populations with heightened effector function. In a contemporary multicenter cohort of 4,411 kidney transplants with 10,214 post-transplant biopsies in the CMV prophylaxis era, CMV seropositivity, indicative of prior infection, was independently associated with a twofold higher hazard of MVI and increased graft failure. This association extended across antibody-mediated and DSA-negative, C4d-negative MVI and acted synergistically with HLA-DSA and missing self. Post-transplant CMV replication and disease were associated with subsequent MVI only in seronegative recipients, consistent with an effect of primary CMV infection. Together, these findings identify CMV infection as a clinically relevant and previously underrecognized determinant of MVI, beyond alloimmune factors.
- Open Access
- 12 March 2026
- Published by Springer Nature in Research Square
Continuous Transcriptomic Indices for Assessing the Spectrum of Kidney Transplant Rejection: International Derivation and Validation Study
Kidney allograft rejection is currently defined by categorical Banff histologic thresholds, despite reflecting a continuous spectrum of immune injury. Here we developed four continuous molecular indices capturing rejection severity and injury stage: antibody-mediated microvascular injury (AMR/MVI), T cell–mediated tubulointerstitial inflammation (TCMR/TI), inflammatory activity and chronic injury. Using transcriptomic profiling of formalin-fixed biopsies with the Banff Human Organ Transplant (B-HOT) panel, indices were trained against continuous histologic scores in 415 biopsies and validated in independent European and US cohorts (total N=2,076). Molecular indices accurately discriminated Banff phenotypes while revealing substantial within-category heterogeneity and clinically meaningful reclassification of intermediate cases. Elevated molecular scores in histologically rejection-free biopsies anticipated subsequent rejection. In multivariable Cox models, all four indices independently predicted five-year graft failure and improved prognostic discrimination beyond histology alone. These continuous molecular indices provide a quantitative framework that complements biopsy interpretation and refines risk stratification across the rejection spectrum.
- 12 March 2026
- Published by Springer Nature in Research Square
Open AccessContinuous Transcriptomic Indices for Assessing the Spectrum of Kidney Transplant Rejection: International Derivation and Validation Study
Kidney allograft rejection is currently defined by categorical Banff histologic thresholds, despite reflecting a continuous spectrum of immune injury. Here we developed four continuous molecular indices capturing rejection severity and injury stage: antibody-mediated microvascular injury (AMR/MVI), T cell–mediated tubulointerstitial inflammation (TCMR/TI), inflammatory activity and chronic injury. Using transcriptomic profiling of formalin-fixed biopsies with the Banff Human Organ Transplant (B-HOT) panel, indices were trained against continuous histologic scores in 415 biopsies and validated in independent European and US cohorts (total N=2,076). Molecular indices accurately discriminated Banff phenotypes while revealing substantial within-category heterogeneity and clinically meaningful reclassification of intermediate cases. Elevated molecular scores in histologically rejection-free biopsies anticipated subsequent rejection. In multivariable Cox models, all four indices independently predicted five-year graft failure and improved prognostic discrimination beyond histology alone. These continuous molecular indices provide a quantitative framework that complements biopsy interpretation and refines risk stratification across the rejection spectrum.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Nephrology
- Vol. 2026 (1)
Disseminated Bartonellosis Masquerading as Autoimmune Glomerulonephritis: A Case Report
Background: Although Bartonella henselae is primarily known for causing self‐limiting cat scratch disease in immunocompetent individuals, it can also lead to severe disseminated infections, particularly in immunocompromised patients. Case Presentation: We present a rare case of disseminated B. henselae infection in a 70‐year‐old man with multiple comorbidities, including a recent aortic valve replacement and pacemaker implantation. The patient initially presented with purpuric skin lesions, progressive renal impairment, and pancytopenia, leading to a preliminary diagnosis of autoimmune glomerulonephritis and treatment with immunosuppressants. Subsequent investigations, including kidney and skin biopsies, revealed C3‐dominant glomerulonephritis and leukocytoclastic vasculitis, respectively. Further imaging uncovered a concurrent lung malignancy, treated with radiotherapy. Five months later, the patient presented with blood culture–negative endocarditis complicated by septic embolic strokes, persisting pancytopenia, and hepatosplenomegaly. Serology and B. henselae PCR of bone marrow confirmed disseminated Bartonella henselae infection. Conclusions: This case highlights the diagnostic challenges of disseminated Bartonella infections, which can mimic autoimmune diseases and delay appropriate treatment. Clinicians should maintain a high index of suspicion to ensure timely diagnosis and management.
- 1 January 2026
- Published by Wiley in Case Reports in Nephrology
- Vol. 2026 (1)
Open AccessDisseminated Bartonellosis Masquerading as Autoimmune Glomerulonephritis: A Case Report
Background: Although Bartonella henselae is primarily known for causing self‐limiting cat scratch disease in immunocompetent individuals, it can also lead to severe disseminated infections, particularly in immunocompromised patients. Case Presentation: We present a rare case of disseminated B. henselae infection in a 70‐year‐old man with multiple comorbidities, including a recent aortic valve replacement and pacemaker implantation. The patient initially presented with purpuric skin lesions, progressive renal impairment, and pancytopenia, leading to a preliminary diagnosis of autoimmune glomerulonephritis and treatment with immunosuppressants. Subsequent investigations, including kidney and skin biopsies, revealed C3‐dominant glomerulonephritis and leukocytoclastic vasculitis, respectively. Further imaging uncovered a concurrent lung malignancy, treated with radiotherapy. Five months later, the patient presented with blood culture–negative endocarditis complicated by septic embolic strokes, persisting pancytopenia, and hepatosplenomegaly. Serology and B. henselae PCR of bone marrow confirmed disseminated Bartonella henselae infection. Conclusions: This case highlights the diagnostic challenges of disseminated Bartonella infections, which can mimic autoimmune diseases and delay appropriate treatment. Clinicians should maintain a high index of suspicion to ensure timely diagnosis and management.
- Top Cited PapersOpen Access
- 26 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10417
Continuous indices to assess the phenotypic spectrum of kidney transplant rejection
The Banff classification for kidney transplant pathology dichotomizes the rejection continuum into distinct diagnostic categories, introducing artificial cutoff points and threshold effects. To better reflect the underlying disease spectrum, in this cohort study of 19,500 biopsies from 8873 patients across 10 centers worldwide, we developed two indices for quantifying antibody-mediated rejection/microvascular inflammation and T-cell-mediated rejection/tubulointerstitial inflammation from histological lesion scores and calculated indices for overall activity and chronicity. These indices demonstrate excellent discrimination for the main diagnostic categories of rejection (AUCs from 0.95 to 0.99), with consistent performance across derivation and validation datasets. These indices strictly confine intermediate phenotypes to low index values and are associated to graft failure even within the diagnostic categories, thus reflecting the underlying rejection continuum. In this work, we demonstrate that four continuous indices provide implementable and interpretable global evaluation of kidney transplant histology that align with the continuous nature of the rejection process regardless of the underlying disease cause.
- 26 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10417
Top Cited PapersOpen AccessContinuous indices to assess the phenotypic spectrum of kidney transplant rejection
The Banff classification for kidney transplant pathology dichotomizes the rejection continuum into distinct diagnostic categories, introducing artificial cutoff points and threshold effects. To better reflect the underlying disease spectrum, in this cohort study of 19,500 biopsies from 8873 patients across 10 centers worldwide, we developed two indices for quantifying antibody-mediated rejection/microvascular inflammation and T-cell-mediated rejection/tubulointerstitial inflammation from histological lesion scores and calculated indices for overall activity and chronicity. These indices demonstrate excellent discrimination for the main diagnostic categories of rejection (AUCs from 0.95 to 0.99), with consistent performance across derivation and validation datasets. These indices strictly confine intermediate phenotypes to low index values and are associated to graft failure even within the diagnostic categories, thus reflecting the underlying rejection continuum. In this work, we demonstrate that four continuous indices provide implementable and interpretable global evaluation of kidney transplant histology that align with the continuous nature of the rejection process regardless of the underlying disease cause.
- Open Access
FCGR3A F158V Genotype Accelerates Progression to Chronic Alloimmune Injury in Antibody-Mediated Kidney Transplant Rejection: A Population-Based Cohort Study
Background: Evidence for involvement of NK cells and monocytes as prime agents in the process of human kidney transplant rejection is expanding quickly. These cells express FCGR3A, used for antibody-dependent cellular cytotoxicity (ADCC) after engagement with donor-specific antibodies on graft cells. A functional genetic polymorphism in the Fc fragment of IgG IIIa receptor (CD16a) gene ( FCGR3A ) results in a high-affinity (V158 allele) or low-affinity receptor (F158 allele). Methods: We studied the impact of the FCGR3A F158V genotype on graft histology, function, and outcomes in a large, unselected observational cohort study of 1259 kidney transplants (40% F/F158, 46% F/V158 and 14% V/V158) with 5435 post-transplant transplant biopsies. Results: Presence of at least one V158 allele was proportionally and significantly associated with a lower rate of C4d without rejection (F/V158, HR=0.51 [0.29-0.92], p=0.026; V/V158, HR=0.28 [0.08-0.90], p=0.033). Additionally, V/V158 was strongly associated with chronic active antibody-mediated rejection (HR=9.13 [1.89–44], p=0.006) and transplant glomerulopathy (HR=1.67 [1.01–2.75], p=0.046). The V/V158 genotype significantly associated with accelerated graft functional decline (−1.68 mL/min/y versus −0.74 mL/min/y (F/F158), p=0.034) and a higher rate of graft failure (HR=1.49 [1.01-2.20], p=0.045). This association was driven by transplants with post-transplant rejection. Conclusions: Our findings suggest that FCGR3A affinity is key in AMR pathobiology. Low affinity of this receptor (F158 allele) might associate with abrogation of effective downstream ADCC, even in the presence of complement activation (C4d deposition), while high affinity of this receptor (V158 allele) might escalate AMR, accelerating evolution to more chronic AMR phenotypes (transplant glomerulopathy). This framework provides an immunobiological link between lower C4d without rejection rates, higher chronic active AMR/ transplant glomerulopathy rates and adverse graft outcomes associated with the FCGR3A V/V158 genotype. Key study findings: V/V158 associates with higher rates of chronic active AMR/transplant glomerulopathy, and lower rates of C4d without rejection V/V158 drives faster graft decline and graft failure, especially in transplants complicated with rejection FCGR3A F158V might link complement activation and ADCC in AMR pathobiology, accelerating chronic alloimmune injury
Open AccessFCGR3A F158V Genotype Accelerates Progression to Chronic Alloimmune Injury in Antibody-Mediated Kidney Transplant Rejection: A Population-Based Cohort Study
Background: Evidence for involvement of NK cells and monocytes as prime agents in the process of human kidney transplant rejection is expanding quickly. These cells express FCGR3A, used for antibody-dependent cellular cytotoxicity (ADCC) after engagement with donor-specific antibodies on graft cells. A functional genetic polymorphism in the Fc fragment of IgG IIIa receptor (CD16a) gene ( FCGR3A ) results in a high-affinity (V158 allele) or low-affinity receptor (F158 allele). Methods: We studied the impact of the FCGR3A F158V genotype on graft histology, function, and outcomes in a large, unselected observational cohort study of 1259 kidney transplants (40% F/F158, 46% F/V158 and 14% V/V158) with 5435 post-transplant transplant biopsies. Results: Presence of at least one V158 allele was proportionally and significantly associated with a lower rate of C4d without rejection (F/V158, HR=0.51 [0.29-0.92], p=0.026; V/V158, HR=0.28 [0.08-0.90], p=0.033). Additionally, V/V158 was strongly associated with chronic active antibody-mediated rejection (HR=9.13 [1.89–44], p=0.006) and transplant glomerulopathy (HR=1.67 [1.01–2.75], p=0.046). The V/V158 genotype significantly associated with accelerated graft functional decline (−1.68 mL/min/y versus −0.74 mL/min/y (F/F158), p=0.034) and a higher rate of graft failure (HR=1.49 [1.01-2.20], p=0.045). This association was driven by transplants with post-transplant rejection. Conclusions: Our findings suggest that FCGR3A affinity is key in AMR pathobiology. Low affinity of this receptor (F158 allele) might associate with abrogation of effective downstream ADCC, even in the presence of complement activation (C4d deposition), while high affinity of this receptor (V158 allele) might escalate AMR, accelerating evolution to more chronic AMR phenotypes (transplant glomerulopathy). This framework provides an immunobiological link between lower C4d without rejection rates, higher chronic active AMR/ transplant glomerulopathy rates and adverse graft outcomes associated with the FCGR3A V/V158 genotype. Key study findings: V/V158 associates with higher rates of chronic active AMR/transplant glomerulopathy, and lower rates of C4d without rejection V/V158 drives faster graft decline and graft failure, especially in transplants complicated with rejection FCGR3A F158V might link complement activation and ADCC in AMR pathobiology, accelerating chronic alloimmune injury
- Open Access
- 5 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (9) , 1940-1953
The impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter study
- 5 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (9) , 1940-1953
Open AccessThe impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter study
- 4 May 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (3) , 54-61
Sjögren’s disease with mixed cryoglobulinemia presenting as a hypertensive emergency with thrombotic microangiopathy: a diagnostic puzzle
We describe the case of a 50-year old woman presenting with hypertension-associated thrombotic microangiopathy (TMA) and nephrotic syndrome as an unusual initial presentation of a cryoglobulinemic glomerulonephritis secondary to primary Sjögren's disease. This case first highlights the importance of a thorough and systemic work-up in patients with TMA, given the broad differential diagnosis and diagnostic complexity. When initial evaluation does not reveal an underlying cause and TMA parameters improve with blood pressure control, a diagnosis of hypertension-associated TMA may be considered. However, hypertension-associated TMA is often secondary to an underlying auto-immune or primary renal disease, warranting further investigation. In this case, kidney biopsy revealed a membranoproliferative glomerulonephritis with hyaline thrombi. Electron microscopy showed subendothelial electron dense deposits, and serum analysis confirmed the presence of mixed cryoglobulins, establishing the diagnosis of cryoglobulinemic glomerulonephritis. Primary Sjögren's disease was suspected based on positive anti-Ro60 and anti-Ro52 antibodies and supported by the presence of sicca symptoms, and was finally confirmed by a positive Schirmer's test. This case illustrates the diagnostic value of a kidney biopsy in identifying the underlying etiology of TMA and it also highlights the importance of considering cryoglobulinemia in the differential diagnosis of membranoproliferative glomerulonephritis.
- 4 May 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (3) , 54-61
Sjögren’s disease with mixed cryoglobulinemia presenting as a hypertensive emergency with thrombotic microangiopathy: a diagnostic puzzle
We describe the case of a 50-year old woman presenting with hypertension-associated thrombotic microangiopathy (TMA) and nephrotic syndrome as an unusual initial presentation of a cryoglobulinemic glomerulonephritis secondary to primary Sjögren's disease. This case first highlights the importance of a thorough and systemic work-up in patients with TMA, given the broad differential diagnosis and diagnostic complexity. When initial evaluation does not reveal an underlying cause and TMA parameters improve with blood pressure control, a diagnosis of hypertension-associated TMA may be considered. However, hypertension-associated TMA is often secondary to an underlying auto-immune or primary renal disease, warranting further investigation. In this case, kidney biopsy revealed a membranoproliferative glomerulonephritis with hyaline thrombi. Electron microscopy showed subendothelial electron dense deposits, and serum analysis confirmed the presence of mixed cryoglobulins, establishing the diagnosis of cryoglobulinemic glomerulonephritis. Primary Sjögren's disease was suspected based on positive anti-Ro60 and anti-Ro52 antibodies and supported by the presence of sicca symptoms, and was finally confirmed by a positive Schirmer's test. This case illustrates the diagnostic value of a kidney biopsy in identifying the underlying etiology of TMA and it also highlights the importance of considering cryoglobulinemia in the differential diagnosis of membranoproliferative glomerulonephritis.